肺癌
癌症研究
细胞毒性T细胞
细胞毒性
癌细胞
癌症
CD8型
免疫系统
A549电池
表皮生长因子受体
抗体
免疫学
医学
生物
病理
内科学
体外
生物化学
作者
Hanchae Cho,Inseong Jung,Hongfang Ju,Moon‐Chang Baek,Kyungmoo Yea
出处
期刊:Cytokine
[Elsevier]
日期:2023-09-01
卷期号:169: 156249-156249
被引量:2
标识
DOI:10.1016/j.cyto.2023.156249
摘要
Lung cancer is a common and highly malignant tumor. Although lung cancer treatments continue to advance, conventional therapies are limited and the response rate of patients to immuno-oncology drugs is low. This phenomenon raises an urgent need to develop effective therapeutic strategies for lung cancer. In this study, we genetically modified human primary CD8+ T cells and obtained antitumor extracellular vesicles (EVs) from them. The engineered EVs, containing interlekin-2 and the anti-epidermal growth factor receptor (EGFR) antibody cetuximab on their surfaces, exhibited direct cytotoxicity against A549 human lung cancer cells and increased cancer cell susceptibility to human peripheral blood mononuclear cell-mediated cytotoxicity. In addition, the engineered EVs specifically targeted the lung cancer cells in an EGFR-dependent manner. Taken together, these findings show that surface engineering of cytokines and antibodies on CD8+ T cell-derived EVs not only enhances their antitumor effects but also confers target specificity, suggesting a potential of modifying the immune cell-derived EVs in cancer treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI